Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00735930 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

NIH

Sponsor class

Conditions

Anemia
Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Thrombocytopenia

Interventions

DRUG: Alvocidib Hydrochloride
DRUG: Lenalidomide
OTHER: Pharmacological Study
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)